ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Astellas Joins With Cytokinetics

by Lisa M. Jarvis
July 1, 2013 | APPEARED IN VOLUME 91, ISSUE 26

Japanese drug firm Astellas Pharma and Cytokinetics have teamed to develop small-molecule skeletal muscle activators. South San Francisco-based Cytokinetics could bring in more than $40 million in milestone and research payments in the first two years of the pact and reap up to $450 million more if drug candidates reach the market. As part of the deal, Astellas gains rights to codevelop CK-2127107, an activator of the fast skeletal muscle troponin complex, now in Phase I studies as a muscle disease treatment. Cytokinetics retains rights to tirasemtiv, a fast skeletal troponin activator in Phase II studies for the treatment of amyotrophic lateral sclerosis.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment